Globus Medical Inc. Class A Common Stock vs PT Telekomunikasi Indonesia Tbk — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while PT Telekomunikasi Indonesia Tbk trades at $12.59 (market cap $12.40B). The key difference: PT Telekomunikasi Indonesia Tbk is the larger of the two by market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.59% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and PT Telekomunikasi Indonesia Tbk for 1 Days on average.
| GMED | TLK | |
|---|---|---|
Market Cap | $10.25B | $12.40B |
Volume | 1,059,528 | 981,144 |
Sector | Health | Media |
52-Week High | $96.82 | $23.43 |
52-Week Low | $58.33 | $12.42 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $9.76B | $13.76B |
Dividend Yield | — | 9.59% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →